Femasys (FEMY) Non Operating Income (2020 - 2026)
Femasys' (FEMY) quarterly Non Operating Income came in at $597644.0 in Q2 2026, up 181.38% on a YoY basis from $212394.9 in Q2 2025, and up 181.38% quarter-over-quarter from -$734356.0 in Q2 2025.
Analysis
Femasys (FEMY) Non Operating Income (2020 - 2026) Analysis & Trends
Femasys (FEMY) has reported Non Operating Income for 7 consecutive years, with $597644.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non Operating Income rose 181.38% year-over-year to $597644.0; the trailing twelve-month figure through Jun 2026 stood at -$968050.0 (up 47.81% YoY), and the FY2025 full-year result was -$1.0 million, down 1.64% from the prior year.
- Non Operating Income climbed to $597644.0 in Q2 2026 per FEMY's latest filing, from -$734356.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $597644.0 in Q2 2026 and bottomed at -$734356.0 in Q2 2025.
- Historically, Non Operating Income has averaged -$74688.7 across 5 years, with a median of $25862.0 in 2022.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income soared 34177.5% in 2023, then slumped 1000.75% in 2024.
- Over 5 years, Non Operating Income stood at $112466.0 in 2022, then sank by 61.41% to $43399.0 in 2023, then plunged by 1000.75% to -$390918.0 in 2024, then tumbled by 87.85% to -$734356.0 in 2025, then jumped by 181.38% to $597644.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $597644.0, -$734356.0, and -$440420.0 for Q2 2026, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn | 82.70 Mn |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn | - |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn | 46.00 Mn |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn | - |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn | 6.60 Mn |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn | - |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn | - |
| 9 | Steris | 21.90 Bn | 21.43 Bn | 684.20 Mn | -12.30 Mn |
| 10 | Femasys | 9.01 Mn | 7.57 Mn | 189,391.00 | 597,644.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 597,644.00 |
| Jun 30, 2025 | -734,356.00 |
| Mar 31, 2025 | -440,420.00 |
| Dec 31, 2024 | -390,918.00 |
| Sep 30, 2024 | -289,262.00 |
| Jun 30, 2024 | -204,173.00 |
| Mar 31, 2024 | -136,868.00 |
| Dec 31, 2023 | 43,399.00 |
| Sep 30, 2023 | 84,359.00 |
| Jun 30, 2023 | 42,454.00 |
| Mar 31, 2023 | 95,417.00 |
| Dec 31, 2022 | 112,466.00 |
| Sep 30, 2022 | 74,346.00 |
| Jun 30, 2022 | 25,862.00 |
| Mar 31, 2022 | -280.00 |
| Dec 31, 2021 | -3,117.00 |
| Sep 30, 2021 | -8,256.00 |
| Jun 30, 2021 | 818,016.00 |
| Dec 31, 2020 | 6,746.00 |
| Sep 30, 2020 | -3,418.00 |